Loading...

Janice Lu, MD, PhD

Title(s)Clinical Professor of Medicine (Clinician Educator)
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089
Phone+1 323 865 0314
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Syracuse University1995All-University Doctoral Prize
    Biannual Ovarian Cancer Research Symposium2002Hematology/Oncology Fellows Award
    New York University Cancer Center2003Translational Research Task Force Award
    SUNY at Stony Brook School of Medicine2005Carol M. Baldwin Breast Cancer Research Award
    SUNY at Stony Brook School of Medicine2010Maffetone Award for Fighting Breast Cancer

    Collapse Overview 
    Collapse Overview
    Dr. Janice Lu is a clinical professor of medicine in the division of medical oncology at the USC Norris Comprehensive Cancer Center. Dr. Lu is certified by the American Board of Internal Medicine and Medical Oncology. She is also a member of the American Society of Clinical Oncology.

    She has extensive experience in clinical trials, breast cancer drug development and has led studies as national protocol chair. She serves as associate director of breast cancer research and director of breast cancer clinical trials at USC Norris Cancer Center.

    Dr. Lu completed her Hematology and Medical Oncology fellowship at New York University School of Medicine. She earned her PhD degree in Molecular Biology with Dr. David Allis, a pioneer in the foundations of epigenetics at Rockefeller University. Prior to joining to USC Norris Cancer Center, she served as an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology at UCLA. Dr. Lu also served as the Director of the Breast Medical Oncology Program at SUNY Stony Brook for eight years.

    Dr. Lu’s career has focused on the management of women with breast cancer in which she excels with her expertise and warm and caring nature. She is dedicated to the cancer community and serves as a board member for the Cancer Support Community in Santa Monica. Her goal is to utilize her science and medical knowledge to work with each patient on a highly individualized basis with state-of-the-art cancer care.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20; 31(9):1157-63. PMID: 23382472.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCTClinical Trials
    2. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 2010 Feb 01; 126(3):669-83. Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, Frohman MA, Golightly MG, Madajewicz S, Chen WT. PMID: 19662651.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    3. Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol. 2008 Oct 01; 1:16. Chu D, Lu J. PMID: 18828924.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    4. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008 Feb; 9(2):117-23. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. PMID: 18221915.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    5. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol. 2008 Mar; 108(3):500-4. Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F. PMID: 18191187.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    6. Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. Hematol Oncol Clin North Am. 2003 Aug; 17(4):969-75. Lu MJ, Sorich J, Hazarika M, Kim M, Del Priore G, Jacobs AJ, Chiang C, Liu PC, Fusco E, Curtin JP, Muggia FM. PMID: 12959186.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Emerging treatments for ovarian cancer. Expert Opin Emerg Drugs. 2003 May; 8(1):203-16. Muggia F, Lu MJ. PMID: 14610922.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    Min Janice's Networks
    Concepts (63)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑